These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 643030)

  • 1. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.
    Drachman DB; Angus CW; Adams RN; Michelson JD; Hoffman GJ
    N Engl J Med; 1978 May; 298(20):1116-22. PubMed ID: 643030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis.
    Lindstrom J; Einarson B
    Muscle Nerve; 1979; 2(3):173-9. PubMed ID: 503104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis.
    Drachman DB; Adams RN; Josifek LF; Self SG
    N Engl J Med; 1982 Sep; 307(13):769-75. PubMed ID: 7110241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process.
    Drachman DB; Angus CW; Adams RN; Kao I
    Proc Natl Acad Sci U S A; 1978 Jul; 75(7):3422-6. PubMed ID: 277944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.
    Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV
    Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions.
    Stanley EF; Drachman DB
    Science; 1978 Jun; 200(4347):1285-7. PubMed ID: 663610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Bungarotoxin displacing antibody in myasthenia gravis.
    Barkas T; Simpson JA
    J Clin Lab Immunol; 1982 Nov; 9(2):113-7. PubMed ID: 7154056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate.
    Tzartos SJ; Sophianos D; Zimmerman K; Starzinski-Powitz A
    J Immunol; 1986 May; 136(9):3231-8. PubMed ID: 3958494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenic patients' IgG causes redistribution of acetylcholine receptors: freeze-fracture studies.
    Pumplin DW; Drachman DB
    J Neurosci; 1983 Mar; 3(3):576-84. PubMed ID: 6827310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
    Vernet-der Garabedian B; Bach JF; Morel E
    Clin Exp Immunol; 1987 Apr; 68(1):130-7. PubMed ID: 3652512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified assay for antibody against the nicotinic acetylcholine receptor in myasthenia gravis.
    Dwyer DS; Bradley RJ; Oh SJ; Kemp GE
    Clin Exp Immunol; 1979 Sep; 37(3):448-51. PubMed ID: 509779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
    Vernet-der-Garabédian B; Morel E; Bach JF
    C R Acad Sci III; 1984; 298(16):449-56. PubMed ID: 6428718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of myasthenic IgG on degradation of junctional acetylcholine receptor.
    Takeo G; Motomura M; Mats H; Ohishi K; Yoshimura T; Tsujihata M; Nagataki S
    Muscle Nerve; 1993 Aug; 16(8):840-8. PubMed ID: 8332137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.
    Zurn AD; Fulpius BW
    Clin Exp Immunol; 1976 Apr; 24(1):9-17. PubMed ID: 949876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.
    Graus YF; de Baets MH; Parren PW; Berrih-Aknin S; Wokke J; van Breda Vriesman PJ; Burton DR
    J Immunol; 1997 Feb; 158(4):1919-29. PubMed ID: 9029134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymyositis: reduction of acetylcholine receptors in skeletal muscle.
    Pestronk A; Drachman DB
    Muscle Nerve; 1985; 8(3):233-9. PubMed ID: 4058467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acetylcholine receptor antibodies in the diagnosis of myasthenia gravis. Study of 406 confirmed cases].
    Toyka KV; Heininger K
    Dtsch Med Wochenschr; 1986 Sep; 111(38):1435-9. PubMed ID: 3757800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lipid-associated acetylcholine receptor as an antigen in diagnosis of myasthenia gravis.
    Raimond F; Vernet-der-Garabedian B; Morel E
    Clin Exp Immunol; 1982 Feb; 47(2):345-50. PubMed ID: 7075027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.